{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-022875","form_type":"8-K","ticker":"MNPR","cik":"0001645469","company_name":"Monopar Therapeutics","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.668465+00:00","generated_at":"2026-06-11T17:52:18.188674+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Monopar Q2 net loss $2.2M ($0.16/shr); camsirubicin at 5th dose level","bullets":["Net loss of $2.2M ($0.16/shr) vs $2.8M ($0.22/shr) in Q2 2022.","Cash and short-term investments $10.2M; cash runway through Sep 2024; needs more capital within 12 mos.","Camsirubicin Phase 1b at 650 mg/m²; two patients showed 18% and 20% tumor reduction; no cardiotoxicity.","MNPR-101 radiopharma advancing toward first-in-human studies potentially by end of 2023.","R&D expenses decreased to $1.6M from $2.1M; G&A slightly up to $0.7M."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-022875","json":"https://secwatch.observer/filing/0001437749-23-022875.json","markdown":"https://secwatch.observer/filing/0001437749-23-022875.md","text":"https://secwatch.observer/filing/0001437749-23-022875.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645469/000143774923022875/0001437749-23-022875-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645469/000143774923022875/mnpr20230808_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T17:52:18.188674+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2a0f82f59ef60f5a8cbaa50ea8a149edf2648a8c","claim":"Monopar Therapeutics reported second quarter ended June 30, 2023 results: net income $2.2 million or $0.16 per share, EPS $0.16 per share.","evidence_excerpt":"Net loss for the second quarter of 2023 was $2.2 million or $0.16 per share compared to net loss of $2.8 million or $0.22 per share for the second quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774923022875/0001437749-23-022875-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Net income","value":"$2.2 million or $0.16 per share"},{"label":"EPS","value":"$0.16 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}